CTMX
CTMX clinical trials: CytomX Therapeutics, Inc.
Every trial on ClinicalTrials.gov where CytomX Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 10
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CTMX on the catalyst calendar · CTMX registry changes
- Primary completion Feb 2029Sponsor estimatePhase 1/Phase 2NCT07900165Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal CancerCytomX Therapeutics · Colo-rectal CancerNot yet recruitingCTMXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2028Sponsor estimatePhase 1NCT06462794First In Human Study of CX-801 in Advanced Solid TumorsCytomX Therapeutics · Solid Tumor, AdultRecruitingCTMXLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2027Sponsor estimatePhase 1NCT06265688First In Human Study of CX-2051 in Advanced Solid TumorsCytomX Therapeutics · Solid Tumor, AdultRecruitingCTMXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 21, 2020ActualPhase 2NCT03993379PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid TumorsCytomX Therapeutics · Solid TumorTerminatedCTMXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 4, 2025ActualPhase 1NCT05387265A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid TumorsCytomX Therapeutics · Solid TumorsTerminatedCTMXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 27, 2020ActualPhase 1/Phase 2NCT03013491PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or LymphomasCytomX Therapeutics · Solid TumorTerminatedCTMXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2, 2023ActualPhase 2NCT04596150Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast CancerCytomX Therapeutics · NeoplasmsCompletedCTMXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2023ActualPhase 1/Phase 2NCT03543813PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCLCytomX Therapeutics · Solid Tumor, AdultCompletedCTMXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 10, 2020ActualPhase 1/Phase 2NCT03149549PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid TumorsCytomX Therapeutics · Solid Tumor, AdultTerminatedCTMXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2020Sponsor estimatePhase 1NCT03706274PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid TumorsCytomX Therapeutics · Solid Tumor, AdultWithdrawnCTMXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner